Avacta Group (LON:AVCT) Announces Quarterly Earnings Results

Avacta Group (LON:AVCT) released its quarterly earnings data on Tuesday. The biotechnology company reported GBX (9.27) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Avacta Group had a negative return on equity of 361.23% and a negative net margin of 30,398.21%.The business had revenue of GBX 11 million for the quarter.

Avacta Group Trading Down 0.9%

LON AVCT opened at GBX 81.30 on Wednesday. Avacta Group has a 12 month low of GBX 26 and a 12 month high of GBX 92. The company has a debt-to-equity ratio of 14,168.75, a current ratio of 0.79 and a quick ratio of 4.96. The company has a market capitalization of £368.70 million, a price-to-earnings ratio of -4.63 and a beta of 1.12. The company’s fifty day moving average price is GBX 72.88 and its two-hundred day moving average price is GBX 67.95.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).